Skip to content

Elastrin Therapeutics

8 viewers · 30d

Total raised

$500K

1 filing since 2024 · latest SAFE filed

Cumulative raised
LAST ROUND
SAFE · $500K
ROUNDS
1
INVESTORS
1
FOUNDED
N/A
HQ
Greenville, SC
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
8

AI overview

Updated

Elastrin Therapeutics, Inc. is an innovative biotechnology company dedicated to creating groundbreaking therapies aimed at reversing cardiovascular diseases and reinstating elasticity in damaged tissues and organs. By addressing the genetic and environmental factors leading to the deterioration of elastin, the company seeks to enhance the quality of life for patients suffering from related health issues.

What sets it apart

Elastrin’s unique focus on the restoration of elastin integrity positions it as a potential leader in addressing root causes of cardiovascular ailments rather than merely treating symptoms.

Funding history

1 round
SAFE+2Sep 11, 2024
Form D/A
+$500K$500K total

Latest SEC filings

via EDGAR · CIK 0001848350
Form D/A · Sep 11, 2024View on EDGAR

Products

1 tracked

ELT-001

Cardiovascular Therapy

ELT-001 is Elastrin Therapeutics' lead product candidate, featuring an innovative formulation of EDTA-loaded nanoparticles that are conjugated with a proprietary monoclonal antibody. This cutting-edge technology is designed to selectively target and eliminate harmful calcifications in areas where elastin has degraded, with the potential to significantly restore the elasticity of blood vessels and various organs.

  • Targeted delivery system via nanoparticle technology
  • Conjugation with a proprietary monoclonal antibody for enhanced efficacy
  • Removes calcification from degraded elastin sites
  • Potentially restores normal function in cardiovascular systems

Links

WebsiteSEC EDGAR filings